Back to Search
Start Over
Changes in right heart haemodynamics and echocardiographic function in an advanced phenotype of pulmonary hypertension and right heart dysfunction associated with pulmonary fibrosis.
- Source :
-
Thorax [Thorax] 2014 Feb; Vol. 69 (2), pp. 123-9. - Publication Year :
- 2014
-
Abstract
- Background: Pulmonary hypertension (PH)-targeted therapy in the setting of pulmonary fibrosis (PF) is controversial; the main clinical concern is worsening of systemic hypoxaemia. We sought to determine the effects of gentle initiation and chronic administration of parenteral treprostinil on right heart function in patients with PF associated with an advanced PH phenotype.<br />Methods: Open-label, prospective analysis of patients with PF-PH referred for lung transplantation (LT). Advanced PH was defined as mean pulmonary artery pressure (mPAP) ≥35 mm Hg. We compared haemodynamics, Doppler echocardiography (DE), oxygenation, dyspnoea and quality of life indices, and 6 min walk distance (6MWD) before and 12 weeks after parenteral treprostinil.<br />Results: 15 patients were recruited in the study. After therapy, there were significant improvements in right heart haemodynamics (right atrial pressure (9.5 ± 3.4 vs 6.0 ± 3.7); mPAP (47 ± 8 vs 38.9 ± 13.4); CI (2.3 ± 0.5 vs 2.7 ± 0.6); pulmonary vascular resistance (698 ± 278 vs 496 ± 229); transpulmonary gradient (34.7 ± 8.7 vs 28.5 ± 10.3); mvO2 (65 ± 7.2 vs 70.9 ± 7.4); and stroke volume index (29.2 ± 6.7 vs 33 ± 7.3)) and DE parameters reflecting right heart function (right ventricular (RV) end diastolic area (36.4 ± 5.2 vs 30.9 ± 8.2 cm(2)), left ventricular eccentricity index (1.7 ± 0.6 vs 1.3 ± 0.5), tricuspid annular planar systolic excursion (1.6 ± 0.5 vs 1.9 ± 0.2 cm)). These changes occurred without significant alteration in systemic oxygenation, heart rate, or mean systemic arterial pressure. In addition, improvements were seen in 6MWD (171 ± 93 vs 230 ± 114), 36-Item Short Form Health Survey Mental Component Summary aggregate (38 ± 11 vs 44.2 ± 10.7), University of California, San Diego Shortness of Breath Questionnaire (87 ± 17.1 vs 73.1 ± 21), and brain natriuretic peptide (558 ± 859 vs 228 ± 340).<br />Conclusions: PH-targeted therapy may improve right heart haemodynamics and echocardiographic function without affecting systemic oxygen saturation in an advanced PH phenotype associated with RV dysfunction in the setting of PF.
- Subjects :
- Aged
Dyspnea drug therapy
Dyspnea etiology
Dyspnea physiopathology
Echocardiography, Doppler
Epoprostenol therapeutic use
Exercise Test methods
Female
Hemodynamics drug effects
Humans
Hypertension, Pulmonary diagnostic imaging
Hypertension, Pulmonary etiology
Hypertension, Pulmonary physiopathology
Male
Middle Aged
Oxygen Consumption drug effects
Phenotype
Pilot Projects
Prospective Studies
Quality of Life
Treatment Outcome
Ventricular Dysfunction, Right diagnostic imaging
Ventricular Dysfunction, Right etiology
Ventricular Dysfunction, Right physiopathology
Antihypertensive Agents therapeutic use
Epoprostenol analogs & derivatives
Hypertension, Pulmonary drug therapy
Pulmonary Fibrosis complications
Ventricular Dysfunction, Right drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1468-3296
- Volume :
- 69
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Thorax
- Publication Type :
- Academic Journal
- Accession number :
- 24431095
- Full Text :
- https://doi.org/10.1136/thoraxjnl-2013-204150